Wolverine Asset Management’s SAB Biotherapeutics SABS Stock Holding History

Wolverine Asset Management’s Portfolio SABS Stock Details SABS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-393	Closed	-$2K	–	2281
2022 Q3	$2K	Hold	393	–	–	﹤0.01%	2257
2022 Q2	$5K	Sell	393 -250	-39%	-$5.25K	﹤0.01%	2126
2022 Q1	$24K	Sell	643 -17	-3%	-$785	﹤0.01%	1728
2021 Q4	$51K	Buy	+660	New	+$61.9K	﹤0.01%	1517
2021 Q3	–	Sell	-13,548	Closed	-$1.35M	–	2298
2021 Q2	$1.35M	Sell	13,548 -1,833	-12%	-$182K	0.01%	536
2021 Q1	$1.51M	Buy	+15,381	New	+$1.54M	0.01%	518

Other funds holding SABS

FPB

First PREMIER Bank Sioux Falls, South Dakota $619M AUM 20.21% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Veritable Wilmington, Delaware $6.46B AUM 17.32% 1-Year Est. Return

WAM

Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SCM

Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return

IFAM

Institutional & Family Asset Management Fort Collins, Colorado $654M AUM 12.29% 1-Year Est. Return

Meteora Capital Boca Raton, Florida $1.36B AUM 21.19% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wolverine Asset Management's SABS Position: Q4 2022 in Review

Wolverine Asset Management sold out of SAB Biotherapeutics (SABS) in Q4 2022, closing a stake of 393 shares — an estimated $2K sold.

Wolverine Asset Management first reported a position in SABS in Q1 2021 and held it in 6 quarters. The position peaked at $1.51M in Q1 2021. 38 funds tracked by Wall St. Rank hold SABS as of Q4 2022.

Wolverine Asset Management reported no remaining SAB Biotherapeutics position as of Q4 2022 after selling out during the quarter.
Wolverine Asset Management sold 393 SAB Biotherapeutics shares in Q4 2022, an estimated $2K.
Wolverine Asset Management first reported a position in SAB Biotherapeutics in Q1 2021 and held it in 6 quarters.
Wolverine Asset Management's SAB Biotherapeutics position peaked at $1.51M in Q1 2021.
38 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q4 2022.

Based on Wolverine Asset Management's 13F filing for Q4 2022, filed 1 Feb 2023.